ASX Release **16 July 2026**
ASX Code: MEM

Quarterly Activities Report and Appendix 4C - Period Ended 30 June 2026

Quarter at a Glance

QUARTERLY REVENUE	CASH ON HAND	CONTRACTED/ CLIENTS COUNTRIES	FY26 CONTRACTED SALES
$150,000[1]	**$1,179,000**	**6/16**	**~$3.0 million**
up 34% on March qtr	up from $420k at 31 Mar	Agreements/countries	vs $2.0m corporate goal

Highlights

- **Delivered a second consecutive record revenue quarter of $150,000[1], taking FY26 revenue to $273,000, with 96% generated during the second half**
- **Executed a 12-month exclusive national supply agreement with Monash IVF Group (ASX: MVF), the Company's largest Felix™ commercial agreement to date, covering its network of 22 Australian clinics**
- **Accelerated UK market entry, with four IVF groups commencing commercial trials, initial orders received**
- **Expanded Felix™ distribution across Southeast Asia through exclusive agreements in Vietnam and, subsequent to quarter end, Thailand, with a combined value of approximately $961,000**
- **Received a further 1,000-cartridge order from MENA commercial partner ITL, taking cumulative orders to 1,800 cartridges within two quarters of contract year one**
- **71% reduction in quarterly operating cash outflows since December, to $422,000, ($831,000 in the March quarter and $1.44 million in the December quarter),**
- **Successfully completed a $1.2 million placement**
- **Regulatory approvals in Vietnam, Turkey and India expected during the September 2026 quarter, activating existing commercial agreements and supporting further sales growth**

Memphasys Limited (ASX: MEM) ("Memphasys" or "the Company") is pleased to provide its quarterly activities report and Appendix 4C cash flow report for the quarter and full year ended 30 June 2026.

[1] The bulk of June quarter revenue was invoiced late in the quarter, meaning the associated cash receipts will be collected in the September 2026 quarter. The Company has already received $23,000 of these receipts since 30 June 2026, with the balance expected to be collected during the September 2026 quarter.

Memphasys Limited
Level 1, 34-36 Richmond Road
Homebush West, NSW 2140

Contact Details
P +612 8415 7300

E info@memphasys.com
W memphasys.com
ABN 33 120 047 556

Executive Summary - A Quarter of Landmark Commercial Agreements and Board Renewal

The June 2026 quarter was the most commercially active in the Company's history, headlined by:

- Record Quarterly revenues of $150,000, up 34% on the previous quarter.
- the execution of its largest-ever Felix™ supply agreement with Monash IVF Group,
- an accelerated United Kingdom (UK) market entry with four clinics commercially trialling Felix™
- first entry into Southeast Asia through commercial agreements with TMSC Viet Nam Medical Technology Company in Vietnam and EnviMed in Thailand, totalling $961,000 in contracted sales and
- a further 1,000-cartridge order from existing MENA commercial partner, ITL.

During the period, the Company also renewed its Board leadership, with David Tasker appointed Non-Executive Chairman on 19 May 2026.

The chart below shows the Company's revenue trend over FY26:



The bulk of June quarter revenue was invoiced late in the quarter, meaning the associated cash receipts will be collected in the September 2026 quarter. The Company has already received $23,000 of these receipts since 30 June 2026.

Chairman David Tasker commented:

"This is our second consecutive record quarter, with revenue climbing to $150,000 following $112,000 in March, and full year revenue now at $273,000. What matters most to the Board is the quality behind that growth - our largest-ever supply agreement with Monash IVF Group, an accelerated start in the UK, repeat ordering from existing MENA customers, and our first two commercial agreements in Southeast Asia. Commercialisation momentum is building across every market we operate in, and with Turkish and Indian regulatory approvals expected shortly, we are well placed to carry this momentum into FY27."

Revenue Performance

Revenue growth in the June quarter was driven by two complementary trends: new customer and market activation, as commercial agreements executed over recent quarters progress towards revenue generation; and expanding utilisation among existing customers, with a number of clinics already using the Felix™ System increasing order volumes as the system becomes further embedded in clinical workflow.

A number of the commercial agreements executed over the past two quarters remain conditional on regulatory approval being obtained in the relevant market.

- Turkish regulatory registration is expected imminently, with ITL orders for that market anticipated during the September 2026 quarter,
- approval from India's Central Drugs Standard Control Organisation (CDSCO - India's medical device regulator) is also expected in the near term, and
- Vietnamese regulatory approval

All these approvals will activate the Company's existing contracted commercial agreements triggering initial Felix™ orders. The Company anticipates a material increase in sales as these approvals are received and agreements are activated.

Together with anticipated new contracts, the successful roll out of the Monash contract and repeat orders from other existing clients, the September quarter sales are expected to be significantly higher again.

Commercial Agreements - Trailing 12 Months

The table below summarises each major commercial agreement executed by the Company over the past 12 months:

Date Signed	Counterparty	Value and Key Terms	Status
8 Sep 2025	ITL (MENA & Turkey)	~$390,000 min. over 5 years. Exclusive across 15+ countries (~353 clinics, ~140,000 IVF cycles p.a.); 2,500-cartridge annual minimum.	Sales commenced - 1,800 of 2,500 annual minimum met; Turkey orders expected in the September 2026 quarter
28 Oct 2025	Andrology Center Coimbatore / Andro Diagnostics (India)	~$98,820 min. in Year 1, rising to ~$148,000 in Year 2 (5-year, non-exclusive). 450 cartridges/quarter; 200+ clinic network.	Awaiting CDSCO approval - expected in the September 2026 quarter
23 Dec 2025	CFA Italia (Europe)	~$925,000 min. over 5 years. 7,500 cartridges minimum, front-loaded (3,000 in years 1-2).	Sales commenced - initial order placed, repeat orders ongoing
1 Jun 2026	TMSC Viet Nam Medical Technology (Vietnam)	~$530,200 over 2 years (~$205,000 Yr1 / ~$325,000 Yr2). Initial order: 100 cartridges + 3 consoles.	Awaiting Vietnamese regulatory approval - expected August 2026
16 Jun 2026	Monash IVF Group (Australia)	Commercial terms confidential. 12-month exclusive national agreement; 3-month rollout at 2 sites before deployment across 22 clinics; quarterly ordering.	Sales commenced - rollout underway at 2 initial sites
1 Jul 2026	IVF Envimed Co., Ltd. (Thailand)	~$430,500 min. over 3 years. Term begins once Thai FDA approval is received. Initial order: 100 cartridges + 3 consoles.	Awaiting Thai FDA approval - expected Q4 CY2026

Note: In addition to the agreements above, four UK IVF groups commenced commercial trials of Felix™ during the quarter following the Company's UK MHRA approval, with initial orders received. These represent early-stage clinical evaluations rather than contracted commercial agreements and are therefore not included in the table.

Collectively, these agreements represent more than A$3 million in contracted minimum revenues over multiple years, diversifying Memphasys' commercial footprint and establishing a growing base of recurring cartridge revenue, with sales recognised as clinics complete onboarding and applicable regulatory approvals are received.

Board and Governance - Change of Chairman

On 19 May 2026, David Tasker was appointed Non-Executive Chairman of Memphasys, succeeding Dr Lindley Edwards. Mr Tasker brings over 20 years of experience in investor relations, media communications and ASX small-cap company strategy as Managing Director of Chapter One Advisors, together with an existing relationship with Memphasys spanning approximately a decade as a consulting adviser and shareholder prior to joining the Board.

Commercial Execution and Regional Performance

Australia (ANZ) - Monash IVF Group National Supply Agreement

On 16 June 2026, the Company executed a 12-month exclusive national supply agreement with Monash IVF Group Limited (ASX: MVF) for the rollout of the Felix™ System across Australia - the largest annual commercial arrangement the Company has entered for Felix™. The agreement follows a longstanding collaboration between the companies and the completion of a pivotal multi-site clinical trial conducted by Monash IVF in 2025 confirming Felix's performance in sperm selection, which is to be presented in Canberra in August at the Fertility Society of Australia & New Zealand (FSANZ) 2026 Conference.

The agreement begins with a three-month rollout across two Monash IVF clinics, covering implementation, staff training, system troubleshooting and the collection of clinical outcome data.

Subject to the successful completion of this initial phase, the full 12-month term will commence, with Felix™ cartridges and consoles deployed across Monash IVF's network of 22 clinics in Australia.

Monash IVF conducted 12,085 stimulated IVF cycles in 2025 and holds approximately 21% of the Australian stimulated IVF market, providing a high-profile reference client to support broader adoption internationally.

Dr Tony Poulton, an experienced med-tech commercial executive with more than 20 years of senior commercial leadership at Cardinal Health and Covidien across ANZ and APAC, together with a scientific background in reproductive endocrinology, has been appointed as a Key Account Manager (ANZ) to oversee implementation of the Monash IVF Group agreement through its commercial trial phase, working under the direction of A/Prof Hassan Bakos, Director - Clinical Engagement and Growth.

United Kingdom - Accelerated Market Entry

On 25 June 2026, the Company announced accelerated commercial progress in the United Kingdom, one of the world's largest fertility treatment markets, undertaking more than 100,000 fertility treatment and preservation cycles annually.

Four UK IVF groups - including organisations conducting more than 10,000 fertility cycles annually, together with leading independent private clinics - are now actively commercially evaluating the Felix™ System, with initial commercial orders received within weeks of the Company's first direct engagement.

The Company remains encouraged by the level of interest from additional UK IVF groups and expects to convert a number of these commercial evaluations into contracts over the coming months.

MENA - ITL 1,000-Cartridge Order and Regional Expansion

On 27 May 2026, MENA commercial partner ITL placed an order for 1,000 Felix™ cartridges across Qatar, UAE, Iraq and Kuwait, including a second console order from Hamad Medical Corporation (HMC), Qatar's largest IVF institution - a commitment that will double HMC's Felix™ throughput capacity and signals institutional adoption beyond trial-phase utilisation. This order takes cumulative ITL orders to 1,800 of the 2,500-cartridge annual minimum order quantities under the commercial agreement, achieved within two quarters of CE Mark approval.

UAE and Kuwait have transitioned from initial evaluation to committed procurement. Turkish regulatory registration is expected in the September quarter, triggering additional orders during the September 2026 quarter, while Egypt, Jordan and other countries are expected to follow later in the year, supported by six newly appointed local commercial partners working alongside ITL across the region.

Southeast Asia - First Commercialisation Agreement (Vietnam)

On 1 June 2026, the Company signed an exclusive two-year commercialisation agreement with TMSC Viet Nam Medical Technology Company for the sale and distribution of Felix™ in Vietnam - Memphasys' first commercial partnership in Southeast Asia.

TMSC Vietnam has placed an initial order for 100 Felix™ cartridges and three consoles to support in-market testing and clinical preparation ahead of commercial launch.

Felix™ registration in Vietnam is expected in August 2026, with the first commercial order anticipated in the September 2026 quarter.

India - Advancing Market Access

The Company continues to progress its regulatory submission with the Central Drugs Standard Control Organisation (CDSCO), India's medical device regulator, with approval expected in the September quarter and representing a near-term catalyst for activation of the Company's existing contracted commercial agreement with Andrology Center Coimbatore / Andro Diagnostics in that market.

Operational Update - New Inventory and Operations Management Platform

During the quarter, the Company implemented a new cloud-based inventory and operations management platform to support its rapidly expanding global commercial footprint. As commercial activity continues to accelerate, the platform provides an integrated solution for inventory management, order processing, demand forecasting, manufacturing planning and commercial lead tracking. This enables real-time visibility of cartridge inventory across international markets, supports production and shipping schedules aligned to forecast demand, and strengthens sales pipeline management as the number of active commercial partners and IVF clinics continues to grow.

With Felix™ now commercially active or under commercial agreement across a growing number of international markets, and the Company continuing to expand its global footprint, this investment provides the operational infrastructure required to efficiently scale commercial operations and support future growth.

Funding Strategy, Cost Discipline and Capital Structure

On 18 June 2026, the Company completed a **$1.2 million placement**, which was confirmed on 26 June 2026 with the issue of 240,000,000 fully paid ordinary shares at $0.005 per share predominantly used to fund the manufacturing and inventory build of Felix™ cartridges to meet the increase in global demand.

The placement was complemented by a 12-month extension of the Company's Peters Investments convertible note, which now matures on 30 June 2027, maintaining the existing $4.2 million principal and 8% coupon.

Cash and cash equivalents on 30 June 2026 totalled **$1.179 million**, compared with **$420,000** on 31 March 2026, providing approximately **2.8 quarters of funding** at the current operating cash outflow rate.

Importantly, the Company continues to demonstrate strong cost discipline while progressing its global commercialisation strategy. Quarterly operating cash outflows have reduced by approximately **71% since the December 2025 quarter**, declining from **$1.441 million** to **$422,000** in the June 2026 quarter, including a further **49% reduction** from the March quarter.

Quarter	Operating Cash Outflows
December 2025 quarter	$1,441,000
March 2026 quarter	$831,000
June 2026 quarter	**$422,000**

This reduction reflects the Company's ongoing cost discipline following the completion of one-off restructuring costs incurred in the December and March quarters. Administration and staff costs reduced further compared to the March quarter, largely reflecting the timing of supplier and payroll payments, while advertising and marketing costs rose over the quarter, driven by the Company's participation in international conferences, including the European Society of Human Reproduction and Embryology (ESHRE).

Related Party Payments

Payments to related parties and their associates during the quarter, as disclosed in Section 6.1 of the accompanying Appendix 4C, totalled $54,000 (March quarter: $135,000; December quarter: $122,000). These payments relate to directors' fees and consulting fees paid to directors and related entities during the June 2026 quarter.

Subsequent Events

On 1 July 2026, subsequent to quarter end, the Company executed an exclusive three-year commercial agreement with IVF Envimed Co., Ltd. for Felix™ across Thailand - a market of 110 registered IVF clinics conducting 20,000-30,000 cycles annually - with a total minimum contracted value of approximately $430,500. An initial order of 100 Felix™ cartridges and 3 consoles has been received, with revenue expected to commence following Thai FDA approval, anticipated within approximately three to six months (Q4 CY2026).

Following the Thailand agreement, total contracted Felix™ sales for FY2026 have reached approximately more than $3.0 million, exceeding the Company's stated corporate goal of $2.0 million, with commercial agreements now in place across Australia, Europe, the United Kingdom, MENA, India, Japan, Vietnam and Thailand.

Europe - ESHRE Conference, London

Director of Clinical Engagement & Growth, A/Prof Hassan Bakos, recently returned from ESHRE in London, where the Memphasys booth attracted significant interest from large global IVF groups, clinicians, embryologists and prospective commercial partners.

The Company held numerous meetings with existing customers and new prospects seeking to better understand the clinical and operational benefits of the Felix™ System, with many potential clients expressing interest in arranging in-clinic evaluations, workflow familiarisation and commercial trial programs.

The strong level of engagement reinforces the Company's view of Europe as a key near-term growth market and contributed to the increase in advertising and marketing expenditure during the quarter.

Outlook

Memphasys enters FY27 with its broadest-ever commercial footprint - anchored by its largest supply agreement to date with Monash IVF Group, accelerated UK market entry, a new Southeast Asian distribution network now spanning Vietnam and Thailand, and continued order growth from its established MENA commercial partner - together with an improved cash

position, a lower cost base, and renewed Board leadership. The Company's focus for the September 2026 quarter and beyond is on:

- Completing the initial Monash IVF Group rollout phase and progressing toward national deployment across its 22-clinic network
- Continued new contracted client growth in Europe and the UK
- Converting expected Turkish and Indian regulatory approvals into activated orders and increased sales
- Building on early UK trial orders into a scaled, recurring customer base across the four engaged IVF groups
- Supporting TMSC Vietnam and IVF Envimed (Thailand) through in-market testing ahead of regulatory registration and first commercial orders
- Continuing to grow order volumes among existing MENA and European clinics as utilisation of the Felix™ System expands
- Leveraging its new inventory and operations management platform to support efficient scaling of global commercial activity
- Continuing to optimise cost structures, manufacturing cost of goods sold (COGS) and margins

Conclusion

The June 2026 quarter was the most commercially significant in Memphasys' history, with the Company executing its largest-ever Felix™ supply agreement, accelerating into the UK market, entering Southeast Asia for the first time, and continuing to build recurring order volumes in its established MENA market, against a backdrop of continued revenue growth, a materially strengthened balance sheet, and renewed Board leadership.

With regulatory approvals anticipated in Vietnam, Turkey and India, contracted FY26 sales of $3+ million exceeding the Company's 2026 A$2 million target, recently executed commercial agreements entering their delivery phase and a strong pipeline of advanced commercial opportunities, Memphasys enters FY27 with significant momentum and is well positioned to accelerate global commercialisation and build a scalable, recurring revenue business.

Authorised by the Board of Memphasys Limited.

Ends

For further information, please contact:

Colin Jacoby
Chapter One Advisors
Tel: +61 439 980 359
E: cjacoby@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

Memphasys' commercial strategy focuses on building contracted sales through direct and distribution-led channels, scaling production to improve margins, and establishing Felix™ as a new global standard in sperm preparation for ART procedures.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Memphasys' current expectations, estimates and projections about the industry in which Memphasys operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement.

Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Memphasys, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Memphasys cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Memphasys only as of the date of this release.

The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Memphasys will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Memphasys Limited	
ABN	**Quarter ended ("current quarter")**
33 120 047 556	30 June 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	118
1.2	Payments for		
	(a) research and development	(3)	(246)
	(b) product manufacturing and operating costs	(65)	(360)
	(c) advertising and marketing	(43)	(104)
	(d) leased assets	(9)	(47)
	(e) staff costs	(110)	(1,020)
	(f) administration and corporate costs	(192)	(1,369)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	1	3
1.5	Interest and other costs of finance paid	-	(366)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	901
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(421)**	**(2,490)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	(3)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**(3)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	1,200	3,964
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(20)	(111)
3.5	Proceeds from borrowings	-	193
3.6	Repayment of borrowings	-	(672)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**1,180**	**3,374**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	420	298
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(421)	(2,490)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(3)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,180	3,374
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**1,179**	**1,179**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	1,179	420
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,179**	**420**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	54
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	4,068	4,068
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**4,068**	**4,068**

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Convertible Note: Peters Investments: $3m plus facilitation fees and interest (maturing 30 June 2027, coupon rate of 8%).

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(421)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,179
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	1,179
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	2.80

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 16 July 2026.....

Authorised by: The Board.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.